INSMED Inc 8K

Insmed Incorporated’s Q2 2026 earnings presentation announces strong revenue growth, higher BRINSUPRI guidance, ARIKAYCE label‑expansion steps, positive TPIP clinical data, and a path to 2027 cash‑flow positivity.

On August 6, 2026, Insmed Incorporated released its second‑quarter 2026 earnings presentation, reporting strong growth from its commercial products BRINSUPRI and ARIKAYCE, raising full‑year 2026 revenue guidance for BRINSUPRI to $1.25–$1.4 billion, reiterating ARIKAYCE full‑year guidance of $450–$470 million, highlighting total Q2 revenues of $425.5 million, and providing operational updates including the filing of a supplemental NDA for ARIKAYCE in newly diagnosed MAC lung disease patients, positive 12‑month open‑label extension data for its investigational TPIP program in pulmonary arterial hypertension, progress of multiple registrational TPIP studies across four indications, continued pipeline advancement (including INS1033), and its expectation to achieve cash flow positivity in 2027 without raising additional capital.

Filing Facts

CIK

1104506

Ticker

INSM

Form

8K

Source Type

fda

Accession

0001140361-26-031502

Alert Tier

7